Shares of Progyny, Inc. (NASDAQ:PGNY – Get Free Report) have earned a consensus rating of “Hold” from the thirteen brokerages that are covering the stock, MarketBeat.com reports. Eight investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $25.42.
PGNY has been the topic of a number of research reports. JPMorgan Chase & Co. cut their target price on shares of Progyny from $31.00 to $22.00 and set an “overweight” rating on the stock in a research report on Thursday, September 19th. Leerink Partners cut their price objective on shares of Progyny from $25.00 to $21.00 and set a “market perform” rating on the stock in a report on Thursday, September 19th. Barclays lowered their target price on shares of Progyny from $30.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday. Canaccord Genuity Group cut their price target on Progyny from $18.00 to $17.00 and set a “hold” rating on the stock in a research note on Wednesday. Finally, Jefferies Financial Group reduced their price target on Progyny from $31.00 to $24.00 and set a “buy” rating on the stock in a research report on Thursday, September 19th.
Get Our Latest Research Report on Progyny
Institutional Investors Weigh In On Progyny
Progyny Price Performance
PGNY stock opened at $13.98 on Friday. The company has a 50 day moving average price of $17.49 and a 200 day moving average price of $23.49. Progyny has a fifty-two week low of $13.77 and a fifty-two week high of $42.08. The stock has a market capitalization of $1.26 billion, a PE ratio of 24.10, a price-to-earnings-growth ratio of 1.62 and a beta of 1.44.
Progyny (NASDAQ:PGNY – Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.26). Progyny had a return on equity of 10.87% and a net margin of 5.03%. The firm had revenue of $286.63 million for the quarter, compared to the consensus estimate of $296.85 million. During the same quarter in the previous year, the firm earned $0.16 EPS. The company’s revenue was up 2.0% compared to the same quarter last year. As a group, equities analysts expect that Progyny will post 0.64 earnings per share for the current fiscal year.
Progyny Company Profile
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
See Also
- Five stocks we like better than Progyny
- Technology Stocks Explained: Here’s What to Know About Tech
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- 3 Monster Growth Stocks to Buy Now
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- Manufacturing Stocks Investing
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.